Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Cineworld Reports "Good" Demand Despite Virus

Fri, 06th Mar 2020 07:43

(Alliance News) - Stock prices in London are set to open lower on Friday on growing investor worries, as governments revealed plans to help tackle the coronavirus crisis.

IG futures indicate the FTSE 100 index is to open 118.73 points, or 1.8%, lower at 6,586.70. The FTSE 100 index closed down 110.16 points, or 0.6%, at 6,705.43. The large-cap index ended lower after three straight days of gains.

The pound was quoted at USD1.2971 early Friday, firm from USD1.2922 at the London equities close Thursday. The euro was at USD1.1227 early Friday, firm from USD1.1185 late Thursday.

The European Central Bank meets next week to consider an action plan to deal with the mounting economic fallout from the coronavirus. But analysts question whether the bank have the monetary firepower to head off the risks resulting from the Covid-19 epidemic.

Christine Lagarde is facing her first major test as ECB president, as the central bank tries to navigate the economic storm unleashed by the spread of the coronavirus around the world.

At the start of the year, analysts had expected little immediate change in the ECB's approach under Lagarde's leadership after she launched a major review of the Frankfurt-based bank's policy instruments.

"Various governments around the world have revealed plans to help control the situation, but after a while dealers started to wonder how bad is the crisis if all these governments are so desperate to announce packages aimed to alleviating the problem. At a certain point, government intervention increases nervousness, and that is what we saw yesterday," said CMC Markets UK analyst David Madden.

"It was a painful day for stock markets yesterday as the number of confirmed cases of coronavirus increased, so the old fears returned to the surface," added Madden.

World health officials have warned that countries are not taking the coronavirus crisis seriously enough, as outbreaks surged across Europe and in the US where medical workers sounded warnings over a "disturbing" lack of hospital preparedness.

Global markets tumbled again Thursday over concerns about the impact on the economy and as countries took more drastic steps to prevent contagion of a disease that has killed more than 3,300 people and infected nearly 100,000 in about 85 nations.

Cases soared in Italy, France, Greece and Iran, while a cruise ship was held off the coast of California to test passengers showing symptoms of the disease – echoing a harrowing episode in Japan several weeks ago that saw hundreds infected on a luxury liner.

The Dow Jones Industrial Average dropped 969.58 points, or 3.6%. The S&P 500 lost 3.4% and the Nasdaq Composite 3.1%.

Against the yen, the dollar was trading at JPY105.89 early Friday in London, down from JPY106.73 late Thursday.

The Nikkei 225 index closed down 2.7% in Tokyo. The Hang Seng index in Hong Kong is down 2.2%. The Shanghai Composite closed down 1.2%.

In early company news, Cineworld Group said it has not "observed any material impact" on its movie theatre admissions due to coronavirus, despite the release of the new James Bond movie postponed to November.

Following an increase in admissions in the first two months of the year, against the same period in the previous year, Cineworld said it continues to see "good" levels of admissions in all of its territories.

Looking ahead, the cinema operator noted that there can be no certainty as to the future impact of COVID-19, but it is taking measures to ensure that it is prepared its business for all possible eventualities.

London-based insurer Aviva has agreed to exit Indonesia by selling its entire shareholding in its joint venture PT Astra Aviva Life to its partner PT Astra International.

This transaction is expected to complete in the final quarter of 2020 and is subject to certain closing conditions, including regulatory approval in Indonesia and the completion of Bangkok Bank Public Co Ltd's acquisition of PT Bank Permata. The shareholders of Bangkok Bank approved the acquisition of Permata Bank on Thursday, Aviva noted.

AstraZeneca said the phase III Danube trial for Imfinzi and Imfinzi plus tremelimumab did not meet the primary endpoints of improving overall survival versus standard-of-care chemotherapy in patients with stage IV bladder cancer.

"The results from this trial will inform our comprehensive phase III development programme in bladder cancer," said Executive Vice President Of Oncology R&D Jose Baselga.

Imfinzi is currently approved for patients with locally advanced or metastatic bladder cancer previously treated with platinum-containing chemotherapy in 15 countries, including the US.

"AstraZeneca remains committed to addressing unmet needs in bladder cancer and the potential for immunotherapy to improve outcomes for these patients," added Baselga.

Among those reporting results, Murray International Trust said it underperformed its benchmark in 2019, with net asset value total return at 12% compared to the 21% returned by its benchmark - a combination of 40% of FTSE World UK Index and 60% of FTSE World ex UK Index.

Murray reported NAV per share as at the end of 2019 of 1,190.0p compared to 1,107.8p reported on the same day a year earlier.

The investment company said it will be paying a dividend of 53.5 pence for 2019, up from 51.5p paid a year earlier.

Looking forward, Murray said it will continue to invest in opportunities across the globe that are not wholly tied to the developed economies and markets.

In addition, Murray appointed Simon Fraser as an independent non-executive director from the start of May.

Fraser had sat on a number of listed company boards in the past, including Barclays and Ashmore. He is currently chair of McInroy & Wood Ltd, the Investor Forum and the independent research boutique TS Lombard. He is also on the board of Fidelity Funds SICAV, Treasurer of the Kings Fund and a trustee of the Abbotsford Trust.

Alliance Trust reported a 21% surge in its NAV per share, which stood at 875.9p as at December 31 versus 723.6p a year ago. The investment company said its total return of 24% outperformed its benchmark, the MSCI All Country World Index (MSCI ACWI), which returned 22%.

Alliance Trust said it will be paying a 13.96p dividend for the year, up 3.0% from 13.55p paid the year before.

"During 2019, we completed the simplification of the trust by selling our subsidiary, Alliance Trust Savings, and virtually all our remaining non-core assets. As a result, we are now fully focused on global equities, something the Board has been working towards for the last four years," said Chair Gregor Stewart.

Looking ahead, the trust added that it expects its new streamlined structure to lead to continued improvement in returns to shareholders.

The economic events calendar on Friday has the US jobs report for February at 1330 GMT.

In commodities, gold was quoted at USD1,670.63 an ounce early Friday, higher than USD1,658.87 late Thursday. Brent oil was at USD49.63 a barrel, down from USD50.91.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.